GeneDx Holdings Corp. (CMLF) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1251351,
    "name": "GeneDx Holdings Corp.",
    "stock_name": "GeneDx Holdings Corp.",
    "full_name": "GeneDx Holdings Corp.",
    "name_url": "stocks-analysis/genedx-holdings-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "161.95",
    "chg": 1.35,
    "chgp": "0.84%",
    "dir": 1,
    "prev_price": "160.60",
    "mcapval": "3,715.17",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US81663L2007",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "492.88 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/genedx-holdings-corp-1251351-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "GeneDx Holdings Corp. Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/genedx-holdings-corp-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-surge-3652138",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/GeneDxHoldingsC_technicaldot_3652138.png",
        "date": "2025-10-28 15:58:13",
        "description": "GeneDx Holdings Corp. has demonstrated strong performance in the Pharmaceuticals & Biotechnology sector, significantly outperforming the S&P 500 across various time frames. The stock has shown impressive returns year-to-date and over the past year, reflecting its resilience and recovery in the current market environment."
      },
      {
        "title": "Is GeneDx Holdings Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-genedx-holdings-corp-technically-bullish-or-bearish-3651534",
        "imagepath": "",
        "date": "2025-10-28 11:45:31",
        "description": "As of 24 October 2025, the technical trend for GeneDx Holdings Corp. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the weekly MACD is mildly bearish and the monthly MACD is bullish. Bollinger Bands are bullish on both weekly and monthly time frames. The KST shows a bullish signal weekly but is mildly bearish monthly. Dow Theory indicates a mildly bearish trend weekly with no trend monthly. The OBV is mildly bullish on both time frames.\n\nGeneDx has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 67.67% compared to the S&P 500's 15.47%, and a one-year return of 118.09% versus 16.90%. Overall, the current technical stance is bullish, driven primarily by the daily moving averages and the bullish Bollinger Bands...."
      },
      {
        "title": "Is GeneDx Holdings Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-genedx-holdings-corp-technically-bullish-or-bearish-3647986",
        "imagepath": "",
        "date": "2025-10-27 11:56:31",
        "description": "As of 24 October 2025, the technical trend for GeneDx Holdings Corp. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the weekly MACD is mildly bearish, contrasting with the monthly MACD which is bullish. Bollinger Bands are bullish on both weekly and monthly time frames. The KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with no trend monthly. Overall, the indicators suggest a bullish sentiment, albeit with some mixed signals in the shorter time frames. There is no available return data to compare the company's performance against the S&P 500...."
      },
      {
        "title": "Is GeneDx Holdings Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-genedx-holdings-corp-technically-bullish-or-bearish-3646519",
        "imagepath": "",
        "date": "2025-10-26 11:31:52",
        "description": "As of 24 October 2025, the technical trend for GeneDx Holdings Corp. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the weekly MACD is mildly bearish, contrasting with the monthly MACD which is bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. The KST shows a bullish weekly signal but is mildly bearish monthly, and the OBV is mildly bullish across both periods. Overall, the stock has significantly outperformed the S&P 500, with a year-to-date return of 67.67% compared to the S&P 500's 15.47%. This strong performance, combined with the bullish indicators, suggests a current bullish stance with moderate strength...."
      },
      {
        "title": "GeneDx Holdings Corp. Shows Significant Operational Growth and Improved Valuation Metrics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genedx-holdings-corp-upgraded-to-strong-buy-amid-improved-valuation-and-profit-growth-3640261",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/GeneDxHoldingsC_mojoScore_3640261.png",
        "date": "2025-10-23 15:54:31",
        "description": "GeneDx Holdings Corp. has recently seen an adjustment in its valuation metrics, reflecting improved financial standing. The company reported a significant increase in operating profit and has maintained positive results for eight consecutive quarters, alongside strong institutional support and robust cash generation capabilities."
      },
      {
        "title": "Is GeneDx Holdings Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-genedx-holdings-corp-overvalued-or-undervalued-3637974",
        "imagepath": "",
        "date": "2025-10-21 12:12:45",
        "description": "As of 17 October 2025, the valuation grade for GeneDx Holdings Corp. has moved from very expensive to attractive, indicating a significant shift in its perceived value. The company appears undervalued, particularly when considering its Price to Book Value of 7.99 and an EV to Sales ratio of 5.92. Despite its negative P/E ratio due to losses, the EV to EBITDA ratio stands at a high 188.80, suggesting that the market may be pricing in future growth potential that has yet to materialize.\n\nIn comparison to its peers, GeneDx's valuation metrics are strikingly different; for instance, Aveanna Healthcare Holdings, Inc. has a P/E ratio of 31.16 and an EV to EBITDA of 12.45, reflecting a more traditional valuation approach. The substantial difference in these ratios highlights GeneDx's current market position. Over the past year, GeneDx has outperformed the S&P 500 with a return of 115.96% compared to the index's 14..."
      },
      {
        "title": "Is GeneDx Holdings Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-genedx-holdings-corp-overvalued-or-undervalued-3634846",
        "imagepath": "",
        "date": "2025-10-20 12:29:57",
        "description": "As of 17 October 2025, the valuation grade for GeneDx Holdings Corp. has moved from very expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, especially when considering its Price to Book Value of 7.99 and an EV to Sales ratio of 5.92, which suggest a potential for growth relative to its current market price. Additionally, the EV to Capital Employed ratio stands at 12.65, highlighting the company's operational efficiency despite its losses.\n\nIn comparison to peers, GeneDx's valuation metrics are strikingly high; for instance, its EV to EBITDA ratio is significantly elevated at 188.80, while Aveanna Healthcare Holdings, Inc. shows a much lower EV to EBITDA of 12.4508. This indicates that GeneDx may be priced for future growth that is not yet realized. Notably, GeneDx has outperformed the S&P 500 with a year-to-date return of 57.35% compared t..."
      },
      {
        "title": "Is GeneDx Holdings Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-genedx-holdings-corp-overvalued-or-undervalued-3632385",
        "imagepath": "",
        "date": "2025-10-19 12:07:19",
        "description": "As of 17 October 2025, the valuation grade for GeneDx Holdings Corp. has moved from very expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, especially considering its current Price to Book Value of 7.99 and an EV to Sales ratio of 5.92, which suggest potential for growth despite its current losses. Additionally, the EV to EBITDA ratio stands at a high 188.80, reflecting significant operational challenges compared to its peers.\n\nIn comparison to its industry, GeneDx's valuation metrics are notably higher than those of Aveanna Healthcare Holdings, which has a P/E of 31.16 and an EV to EBITDA of 12.45, suggesting that GeneDx may have room for improvement in operational efficiency. The company has outperformed the S&P 500 with a year-to-date return of 57.35% compared to the index's 13.30%, reinforcing the notion that despite its current challe..."
      },
      {
        "title": "GeneDx Holdings Corp. Experiences Evaluation Revision Amid Strong Market Performance and Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/genedx-holdings-corp-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-strong-performance-3601370",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/GeneDxHoldingsC_technicaldot_3601370.png",
        "date": "2025-10-07 21:01:04",
        "description": "GeneDx Holdings Corp. has recently revised its evaluation amid changing market conditions. The company has shown impressive performance over the past year, significantly outperforming the S&P 500. Technical indicators suggest a generally positive outlook, although some mixed signals indicate variability in momentum as it navigates the biotechnology sector."
      }
    ],
    "total": 20,
    "sid": "1251351",
    "stock_news_url": "https://www.marketsmojo.com/news/genedx-holdings-corp-1251351"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

GeneDx Holdings Corp. Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-10-28 15:58:13

GeneDx Holdings Corp. has demonstrated strong performance in the Pharmaceuticals & Biotechnology sector, significantly outperforming the S&P 500 across various time frames. The stock has shown impressive returns year-to-date and over the past year, reflecting its resilience and recovery in the current market environment.

Is GeneDx Holdings Corp. technically bullish or bearish?

2025-10-28 11:45:31

As of 24 October 2025, the technical trend for GeneDx Holdings Corp. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the weekly MACD is mildly bearish and the monthly MACD is bullish. Bollinger Bands are bullish on both weekly and monthly time frames. The KST shows a bullish signal weekly but is mildly bearish monthly. Dow Theory indicates a mildly bearish trend weekly with no trend monthly. The OBV is mildly bullish on both time frames. GeneDx has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 67.67% compared to the S&P 500's 15.47%, and a one-year return of 118.09% versus 16.90%. Overall, the current technical stance is bullish, driven primarily by the daily moving averages and the bullish Bollinger Bands....

Is GeneDx Holdings Corp. technically bullish or bearish?

2025-10-27 11:56:31

As of 24 October 2025, the technical trend for GeneDx Holdings Corp. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the weekly MACD is mildly bearish, contrasting with the monthly MACD which is bullish. Bollinger Bands are bullish on both weekly and monthly time frames. The KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with no trend monthly. Overall, the indicators suggest a bullish sentiment, albeit with some mixed signals in the shorter time frames. There is no available return data to compare the company's performance against the S&P 500....

Is GeneDx Holdings Corp. technically bullish or bearish?

2025-10-26 11:31:52

As of 24 October 2025, the technical trend for GeneDx Holdings Corp. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the weekly MACD is mildly bearish, contrasting with the monthly MACD which is bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. The KST shows a bullish weekly signal but is mildly bearish monthly, and the OBV is mildly bullish across both periods. Overall, the stock has significantly outperformed the S&P 500, with a year-to-date return of 67.67% compared to the S&P 500's 15.47%. This strong performance, combined with the bullish indicators, suggests a current bullish stance with moderate strength....

GeneDx Holdings Corp. Shows Significant Operational Growth and Improved Valuation Metrics

2025-10-23 15:54:31

GeneDx Holdings Corp. has recently seen an adjustment in its valuation metrics, reflecting improved financial standing. The company reported a significant increase in operating profit and has maintained positive results for eight consecutive quarters, alongside strong institutional support and robust cash generation capabilities.

Is GeneDx Holdings Corp. overvalued or undervalued?

2025-10-21 12:12:45

As of 17 October 2025, the valuation grade for GeneDx Holdings Corp. has moved from very expensive to attractive, indicating a significant shift in its perceived value. The company appears undervalued, particularly when considering its Price to Book Value of 7.99 and an EV to Sales ratio of 5.92. Despite its negative P/E ratio due to losses, the EV to EBITDA ratio stands at a high 188.80, suggesting that the market may be pricing in future growth potential that has yet to materialize. In comparison to its peers, GeneDx's valuation metrics are strikingly different; for instance, Aveanna Healthcare Holdings, Inc. has a P/E ratio of 31.16 and an EV to EBITDA of 12.45, reflecting a more traditional valuation approach. The substantial difference in these ratios highlights GeneDx's current market position. Over the past year, GeneDx has outperformed the S&P 500 with a return of 115.96% compared to the index's 14...

Is GeneDx Holdings Corp. overvalued or undervalued?

2025-10-20 12:29:57

As of 17 October 2025, the valuation grade for GeneDx Holdings Corp. has moved from very expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, especially when considering its Price to Book Value of 7.99 and an EV to Sales ratio of 5.92, which suggest a potential for growth relative to its current market price. Additionally, the EV to Capital Employed ratio stands at 12.65, highlighting the company's operational efficiency despite its losses. In comparison to peers, GeneDx's valuation metrics are strikingly high; for instance, its EV to EBITDA ratio is significantly elevated at 188.80, while Aveanna Healthcare Holdings, Inc. shows a much lower EV to EBITDA of 12.4508. This indicates that GeneDx may be priced for future growth that is not yet realized. Notably, GeneDx has outperformed the S&P 500 with a year-to-date return of 57.35% compared t...

Is GeneDx Holdings Corp. overvalued or undervalued?

2025-10-19 12:07:19

As of 17 October 2025, the valuation grade for GeneDx Holdings Corp. has moved from very expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, especially considering its current Price to Book Value of 7.99 and an EV to Sales ratio of 5.92, which suggest potential for growth despite its current losses. Additionally, the EV to EBITDA ratio stands at a high 188.80, reflecting significant operational challenges compared to its peers. In comparison to its industry, GeneDx's valuation metrics are notably higher than those of Aveanna Healthcare Holdings, which has a P/E of 31.16 and an EV to EBITDA of 12.45, suggesting that GeneDx may have room for improvement in operational efficiency. The company has outperformed the S&P 500 with a year-to-date return of 57.35% compared to the index's 13.30%, reinforcing the notion that despite its current challe...

GeneDx Holdings Corp. Experiences Evaluation Revision Amid Strong Market Performance and Dynamics

2025-10-07 21:01:04

GeneDx Holdings Corp. has recently revised its evaluation amid changing market conditions. The company has shown impressive performance over the past year, significantly outperforming the S&P 500. Technical indicators suggest a generally positive outlook, although some mixed signals indicate variability in momentum as it navigates the biotechnology sector.

View All News